The predicted human erbB-3 gene product is closely related to epidermal growth factor receptor (EGFR) and erbB-2, which have been implicated as oncogenes in model systems and human neoplasia. We expressed the erbB-3 coding sequence in NIH 3T3 fibroblasts and identified its product as a 180-kDa glycoprotein, gplsOerbB-3. Tunicamycin and pulsechase experiments revealed that the mature protein was processed by N-linked glycosylation of a 145-kDa erbB-3 core polypeptide. The intrinsic catalytic function of gpl8OerbB3 was shown by its ability to autophosphorylate in vitro. Liganddependent signaling of its cytoplasmic domain was established employing transfectants that express a chimeric EGFR/erbB-3 protein, gplSOI FR/erbB-3* EGF induced tyrosine phosphorylation of the chimera and promoted soft agar colony formation of such transfectants. These fimdings combined with the detection of constitutive tyrosine phosphorylation of gpl8OerbB3 in 4 of 12 human mammary tumor cell lines implicate the activated erbB-3 product in the pathogenesis of some human malignancies.
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A small family of growth factor receptors with the erbBI epidermal growth factor receptor (EGFR) as a prototype has been frequently implicated in malignancy. The EGFR and the related erbB-2 gene are frequently overexpressed in the presence or absence of gene amplification in various human tumors (1) (2) (3) . Moreover, they can become activated by mutations that constitutively enhance the catalytic function of their encoded proteins (4, 5) . When such abnormalities are reproduced in model systems, these receptors have been shown capable of conferring the malignant phenotype (6) (7) (8) (9) , supporting their critical role in the development of human neoplasia.
Recently, we have identified a third family member, designated erbB-3 (10) . The erbB-3 coding sequence predicts a receptor-like tyrosine kinase with close similarity to the EGFR and erbB-2 proteins. Though normally expressed in cells of epithelial and neuroectodermal origin, increased erbB-3 transcript levels were detected in some human breast tumor cell lines. These findings raised the possibility that overexpression of this gene plays a role in some human epithelial malignancies (10) . Our present studies were undertaken in an effort to identify and characterize the normal erbB-3 gene product. By analysis of an EGFR/erbB-3 chimeric receptor, we demonstrate that EGF-dependent activation of the erbB-3 catalytic domain results in a proliferative response in transfected NIH 3T3 cells. Finally, we show that some human mammary tumor cell lines exhibit a dramatic elevation of steady-state erbB-3 tyrosine phosphorylation implying functional erbB-3 activation in these tumor cells.
MATERIALS AND METHODS
Engineering of LTR-erbB-3 Expression Vector and DNA Transfection. The pZlPneo expression vector (11) 
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synthetic peptides in the carboxyl-terminal erbB-3 coding sequence (10): MK4 (1191-1205), EDEDEEYEYMNRRRR; MK5 (1254-1268), TTPDEDYEYMNRQRD. For immunization, peptides were coupled to thyroglobulin using glutaraldehyde.
Protein Analysis. Protein lysates were prepared in StaphA buffer (15) containing the protease inhibitors phenylmethylsulfonyl fluoride (1 mM) and aprotinin (10 ,g/ml; Boehringer Mannheim). For the analysis of phosphotyrosine (P-Tyr) proteins, the phosphatase inhibitors sodium orthovanadate (2 mM) and sodium pyrophosphate (10 mM) were added. Immunoblot analysis using peptide antisera was essentially conducted as reported (15) . An EGFR peptide antiserum was generated against a carboxyl-terminal epitope of the receptor (E7) as described (16) . For the detection of P-Tyr proteins, membranes were blocked in phosphate-buffered saline (PBS) containing 5% bovine serum albumin (BSA) and immunostained with a mixture of monoclonal anti-P-Tyr antibodies (PY20 and PY69; ICN) diluted 1:500 in PBS containing 1% BSA. Filters were washed with PBS containing 0.05% Tween 20. Immunoprecipitation was conducted as described (17) using GammaBind G agarose (Pharmacia) to collect the immunocomplexes. The beads were coupled with goat antimouse IgG second antibody (Boehringer Mannheim) in immunoprecipitations using erbB-3 or EGFR monoclonal antibodies. A commercially available monoclonal antibody, AB-1 (Oncogene Sciences, Mineola, NY), reactive with the EGFR extracellular domain, was employed for immunoprecipitation of EGFR and EGFR/erbB-3 proteins. For in vitro kinase assays, 4 mg total lysates were precleared with GammaBind G agarose. Following immunoprecipitation, washed immunocomplexes were equilibrated in autokinase buffer containing 40 mM Hepes (pH 7.5), 10 mM MgCl2, 3 mM MnCl2, and 0.05% Triton. The immunocomplexes were subsequently divided for immunoblot analysis or immuno- 
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Fibroblasts. For structural and functional characterization of the erbB-3 gene product, we inserted the complete erbB-3 open reading frame (10) into a modified ZIPneo vector (11) , placing the cDNA under the transcriptional control of the Moloney murine leukemia virus long-terminal-repeat sequence (LTR-erbB-3). NIH 3T3 fibroblasts were transfected with LTR-erbB-3 or LTR-neo control DNA and cultured in the presence or absence of the selective drug G418. Under conditions in which efficient drug resistance (6 x 103 colonies per pmol) was conferred by LTR-erbB-3, no transformed foci were detectable. In contrast, LTR-erbB-2 or EGF-triggered LTR-EGFR induced morphological transformation of NIH 3T3 cells with efficiencies of around 1.2 x 104 per pmol and 2.3 x 102 per pmol, respectively, as described (6, 8) .
To test for expression of the erbB-3 protein, we developed two polyclonal rabbit antisera against synthetic peptides encompassing residues 1191-1205 (MK4) or 1254-1268 (MK5) within the carboxyl terminus of the predicted erbB-3 product (10) . Immunoblot analysis of lysates from markerselected LTR-neo and LTR-erbB-3 transfectants revealed a major 180-kDa band only in LTR-erbB-3 cells. This band was independently recognized by both antisera (Fig. 1A) . There was no cross-reactivity of either antiserum with the related EGFR or erbB-2 proteins overexpressed in NIH 3T3 cells. Immunoreactivity of either antiserum with the 180-kDa band in LTR-erbB-3 transfectants was competitively inhibited by the antigenic peptide, whereas MK4 reactivity with a faint 125-kDa band was not affected by peptide competition (Fig.  1A) . These results established specificity of erbB-3 protein detection by both polyclonal antisera. By comparison, the 180-kDa erbB-3 protein migrated distinctly slower than the 170-kDa EGFR and slightly faster than the 185-kDa erbB-2 protein (data not shown). The Mature erbB-3 Product, gpl80erbB-3, Represents a Catalytically Active Glycoprotein Associated with the Cell Membrane. To characterize processing of the erbB-3 protein, we performed immunoprecipitation experiments with MK5 antiserum. Metabolic labeling of LTR-erbB-3 transfectants in the presence or absence of tunicamycin demonstrated that the 145-kDa erbB-3 core polypeptide is modified by N-linked glycosylation (Fig. 1B) . Pulse-chase analysis further indicated cotranslational processing, resulting in a predominant 170-kDa precursor protein in addition to faint erbB-3-specific bands of 150 kDa and 160 kDa, following 15 min of pulselabeling (Fig. 1C) . The mature 180-kDa erbB-3 protein appeared after 0.5 h of chase, and the majority was converted into gp180erbB3 by 1 h. By analysis of further time points, we estimate an approximate half-life of 2-3 h (Fig. 1C) . Thus, in NIH 3T3 cells, gp180erbB-3 exhibits an apparently faster turnover than the EGFR, for which a biosynthesis time of 3 h and approximate half-life of 3-6 h have been reported (18) .
For immunolocalization of the erbB-3 protein, an erbB-3-specific monoclonal antibody, MAb E3-1, was raised against the recombinantly expressed protein. MAb E3-1 specifically immunoprecipitated gp180erbB3 from LTR-erbB-3 transfectants ( Fig. 2A) and did not exhibit cross-reactivity with the EGFR or erbB-2 proteins (data not shown). Immunofluorescence analysis revealed heterogeneous membrane immunostaining of formalin-fixed LTR-erbB-3 cells using MAb E3-1 but not with a nonspecific mouse immunoglobulin of matching isotype (Fig. 2B) . MAb E3-1-specific membrane fluorescence of native LTR-erbB-3 cells (Fig. 2B) indicated that gpl80erbB-3 was expressed at the cell surface, as expected for a membrane-anchored protein.
To investigate its function, we next analyzed the erbB-3 protein for in vitro kinase activity. LTR-erbB-3 and control LTR-neo cell lysates were first immunoprecipitated with E3-1 followed by immunoblot analysis with MK4 antiserum (Fig. 3A) . When the same immunoprecipitates were incubated in autokinase buffer containing [y_32P]ATP, a predominant 180-kDa phosphoprotein was labeled only in immunoprecipitates containing the erbB-3 protein (Fig. 3B) . These findings indicated that gpl80erbB-3 possessed intrinsic protein kinase activity. To assess its enzymatic activity in vivo, LTR-erbB-3 lysates were subjected to immunoprecipitation with P-Tyr-specific monoclonal antibodies (anti-P-Tyr) followed by immunoblotting with MK4 antiserum. As shown in Fig. 3C , the erbB-3 protein was recovered from anti-P-Tyr immunoprecipitates, and immunodetection was competitively inhibited either by phenyl phosphate in the immunoprecipitation or the erbB-3 peptide in Western blot analysis. These findings indicated that recombinant gpl80erbB-3 expressed in NIH 3T3 cells was chronically phosphorylated on tyrosine residues. EGF-Dependent Signaling by an EGFR/erbB-3 Chimeric Receptor. To explore erbB-3 signaling, we utilized a chimeric receptor, LTR-EGFR/erbB-3 containing the ligand-binding domain of the closely related EGF receptor (amino acids 1-682) and the intracellular portion of erbB-3 (amino acids 681-1342; unpublished data). Transfection of NIH 3T3 cells with this construct did not result in detectable focus formation either in the presence or absence of EGF. To investigate ligand dependence of erbB-3 enzymatic activity, we compared in vivo tyrosine phosphorylation of the chimeric receptor in the presence or absence of EGF. This protein, EGFR (8) , and erbB-3 proteins from independent transfectants were enriched by immunoprecipitation and subjected to immunoblot analysis with either anti-P-Tyr or the appropriate specific antiserum.
As shown in Fig. 4 , the steady-state level of tyrosine phosphorylated gp180erbB-3 in NIH 3T3 cells was not altered upon EGF exposure (lanes 1 and 2) . The chimeric EGFR/ erbB-3 receptor that was expressed as a 180-kDa protein, gpl80EGFR/erbB-3, displayed a low but detectable level of tyrosine phosphorylation in serum-free medium (lane 3). However, EGF triggering of the chimera resulted in a substantial increase in tyrosine phosphorylation, demonstrating EGF-dependent activation of erbB-3 catalytic function (lane 4). The wild-type EGFR showed a somewhat higher level of EGF-dependent tyrosine phosphorylation under the same conditions (lane 6). Of note, the relative level of gpl8oerbB-3 tyrosine phosphorylation was comparable to that of the EGF-activated chimeric receptor expressed at a similar pro- tein level, implying constitutive activation of erbB-3 catalytic properties in LTR-erbB-3 transfectants. We next assessed the biological effects of activated erbB-3 catalytic function by testing the transfectants for anchorageindependent growth (Table 1) . LTR-neo controls (3 x 103 EGF binding sites per cell) failed to exhibit significant soft agar growth in the presence or absence of EGF. In contrast, EGF induced LTR-EGFR/erbB-3 (1 x 106 binding sites) and LTR-EGFR transfectants (3 x 106 binding sites) to form colonies, although the latter showed greater numbers (Table  1) as well as increased colony size (data not shown). Conversely, the LTR-erbB-3 transfectant, which expressed 0.6-1 x 106 erbB-3 molecules per cell as compared by immunoblotting with the chimeric receptor transfectant, displayed EGF-independent colony formation with an efficiency similar to that of EGF-activated LTR-EGFR/erbB-3 cells ( Table  1 ). All of these findings establish that ligand activation of a chimeric EGFR/erbB-3 receptor causes mitogenic signaling in NIH 3T3 cells. Furthermore, chronic tyrosine phosphorylation of erbB-3 in LTR-erbB-3 transfectants is associated with its constitutive signaling in these cells.
Evidence for Activated erbB-3 Signaling Function in Human Breast Tumor Cells. The availability of erbB-3-specific anti- (Fig. 5) . The lowest levels were observed in BT20 and MDA-MB175 cell lines (Fig. 5) Immunoblot analysis of the same immunoprecipitates with anti-P-Tyr antibodies revealed that tyrosine phosphorylation of the native erbB-3 product was undetectable in eight of the tumor cell lines, including MDA-MB134, MDA-MB361, and MDA-MB468, which harbored increased erbB-3 protein levels. In contrast, the erbB-3 protein expressed by four cell lines, including MDA-MB453, BT474, MDA-MB175, and SK-BR-3, was chronically phosphorylated on tyrosine (Fig.  5, lanes 5, 7, 9 Finally, our demonstration of in vitro kinase activity established that recombinant gpl8oerbB-3 possessed catalytic function. A 160-kDa protein has been reported for erbB-3 cDNA transiently expressed in COS cells (19) . Although functional activity has not been demonstrated for this protein, it remains to be'determined whether this lower molecular mass species reflects incomplete processing or some structural difference in its coding sequence. Although the erbB-3 tyrosine kinase domain shares >60%o amino acid identity with the EGFR and erbB-2 proteins, there are single amino acid substitutions in highly conserved residues shared among known tyrosine kinases. This has raised the question as to whether erbB-3 actually harbors intrinsic catalytic activity involved in signal propagation instead of signal attenuation as has been postulated for certain other receptor tyrosine kinase-like molecules (20) . Most notably, codon 834 within the tyrosine kinase domain predicts asparagine in erbB-3, whereas aspartate is present at this position in essentially all known protein kinases (10, 19, 21) . Moreover, substitution of asparagine for aspartate at this position abolishes c-kit and v-fps tyrosine kinase activity (22, 23) . Our characterization of the erbB-3 cytoplasmic domain demonstrated not only its catalytic function but also the ability to transduce a mitogenic signal. Thus, the erbB-3 gene encodes a membrane-spanning molecule possessing all properties of a functional growth factor receptor.
Constitutive activation of erbB-3 catalytic activity was demonstrated in LTR-erbB-3 transfectants. These results raise the possibility that NIH 3T3 cells may express an erbB-3 ligand. If so, this putative ligand would unlikely interact with the EGFR, since overexpression ofthe latter in NIH 3T3 cells is not associated with its tyrosine phosphorylation in the absence of exogenous EGF. We further established that EGF neither enhanced in vivo tyrosine phosphorylation of gpl80erbB-3 nor elicited a mitogenic response in LTR-erbB-3 cells. Additional ligands of the EGF family including transforming growth factor a (24) , amphiregulin (25) , and heparinbinding EGF (26) have also failed to stimulate gp180erbB-3 tyrosine phosphorylation or DNA synthesis in LTR-erbB-3 cells (unpublished observations). Though a low-affinity interaction of known EGF-related ligands with gpl80erbB-3 cannot be excluded, our findings suggest that erbB-3 and EGFR proteins possess distinct ligand specificities. EGFR and erbB-2 genes have been implicated as oncogenes based upon demonstration of their overexpression and constitutive activation in various human tumors (15, 18, (27) (28) (29) (30) (31) . Our present findings argue strongly that the most recently identified family member, erbB-3, is activated in some human breast tumors. Overexpression of the erbB-3 protein did not invariably correlate with its chronic tyrosine phosphorylation. Hence, erbB-3 activation may involve autocrine stimulation or subtle genetic alterations. In addition to breast tumors, expression ofthe erbB-3 transcript has been observed in a wide range of human carcinomas including colon, lung, kidney, pancreas, and skin (10, 32) . This prompts the search for evidence of erbB-3 activation as an oncogene in these other common human cancers as well.
